Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22680124 | 0.89 | HPGD (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL23207055 | 0.89 | HPGD (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL31319964 | 0.89 | HPGD (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL18340953 | 0.87 | HPGD (0.58) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL20356770 | 0.84 | HPGD (0.55) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL696090 | 0.82 | HPGD (0.62) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL310117 | 0.82 | GPR119 (0.67) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL56417 | 0.82 | HPGD (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| Iodide SCHEMBL362954 | 0.81 | HPGD (0.57) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| Iodide SCHEMBL1484699 | 0.81 | EPHX1 (0.58) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036731-A | CB1 receptor inverse agonist compound, pharmaceutical composition, preparation method and application thereof | 北京康辰药业股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023199238-A1 | NOVEL COMPOUNDS TO TREAT CYTOKINE RELATED DISORDERS | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023199238-A1 | NOVEL COMPOUNDS TO TREAT CYTOKINE RELATED DISORDERS | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023134266-A1 | 2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR | 苏州浦合医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-110392679-B | Heterocyclic compounds useful as dual ATX/CA inhibitors | 豪夫迈·罗氏有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20190127347-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-05-02 | — | — | US | disclosed |
| EP-3466943-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170204123-A1 | Gold (I)-Phosphine Compounds as Anti-Bacterial Agents | AUSPHERIX LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| EP-1642880-A1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| EP-1404672-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| EP-1404672-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030100567-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003000687-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| CN-1091741-A | Tartronic acid and acetal ether thereof and O-ester | DOMPE FARMACEUTICI SPA (IT) | 1994-09-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | HPGD 958/4885RECQL 2724/4885EPHX1 2508/4885 |
| US-20190127347-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HPGD 3324/4885RECQL 108/4885EPHX1 837/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | HPGD 283/4885RECQL 3176/4885EPHX1 3913/4885 |
| US-20170204123-A1 | Gold (I)-Phosphine Compounds as Anti-Bacterial Agents | RER1, CHRM1, ME1 | HPGD 3057/4885RECQL 1904/4885EPHX1 1863/4885 |
| US-20030100567-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | HPGD 2417/4885RECQL 4074/4885EPHX1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.